We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Saliva Testing for COVID-19 Quicker, Safer than Nasal Swabs

By LabMedica International staff writers
Posted on 23 Mar 2022

Early in the COVID-19 pandemic, the urgent need to increase testing was accompanied by a shortage of supplies, notably nasal swabs, which were then the standard method for collecting samples for testing. More...

Research conducted in order to come up with a solution to this problem has now found that genetic testing of saliva samples identifies the SARS-CoV-2 virus more quickly than testing of nasal swabs.

To identify people with COVID-19, investigators at the University of Maryland (College Park, MD, USA) began conducting weekly tests of saliva samples from healthy community volunteers in May 2020 and continued over the next two years. Of the asymptomatic volunteers who tested positive, the researchers found that those patients would typically show symptoms a day or two later, making them wonder if saliva was better at catching pre-symptomatic patients than traditional nasal swabs.

To answer that question, the researchers used data from a companion study of close contacts of people with confirmed cases of COVID-19. In the study, the team collected saliva and mid-turbinate nasal swab samples from contacts every two or three days during their quarantine period. All the samples were tested using real-time reverse transcription polymerase chain reaction (RT-PCR) to detect SARS-CoV-2 and measure how much viral RNA was in the samples. The researchers then analyzed how these results changed in the days before and after symptom onset. The findings revealed that early in the course of infection, saliva was significantly more sensitive than mid-turbinate nasal swabs, notably so before the onset of symptoms. The study also noted that previous studies had shown that pre-symptomatic transmission plays a greater role than symptomatic transmission of SARS-CoV-2.

These findings have implications for improving public acceptance of COVID-19 testing, reducing the cost of mass COVID-19 screening and improving the safety of healthcare workers who conduct testing. In the latter case, saliva self-testing avoids the close contact between patient and healthcare worker that nasal swabbing entails and avoids causing patients to cough and sneeze, thereby spreading virus particles as a result of swabbing the sensitive nasal passages, as well as discomfort to patients.

“Our research supports the use of saliva in large-scale screening in schools and workplaces, as a means of improving screening rates, as well as early detection,” said coauthor Donald K. Milton, M.D., DrPH, a professor of occupational and environmental health at the Institute for Applied Environmental Health, University of Maryland School of Public Health, College Park. “We expect that if rapid saliva tests become available, they could be a major advance from the current nasal swab-based rapid tests.”

Related Links:
University of Maryland 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19, Flu A/B Multiplex RT-PCRTest
TaqPath COVID-19, FluA, FluB Combo Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.